Current drugs available in clinic for Alzheimer's disease (AD) treatment can only alleviate
disease symptoms without clearly curing or delaying the process of AD. And some AD drugs …

Here, we describe a new family of melatonin–N, N-dibenzyl (N-methyl) amine hybrids that
show a balanced multifunctional profile covering neurogenic, antioxidant, cholinergic, and …

A novel family of cinnamic acid derivatives has been developed to be multifunctional
cholinesterase inhibitors against AD by fusing N-benzyl pyridinium moiety and different …

Most neurological diseases have a multifactorial nature and the number of molecular
mechanisms discovered as underpinning these diseases is continuously evolving. The old …

The β-carboline skeleton is prevalent in a vast collection of naturally present alkaloids. Most
of these alkaloids and their derivatives have been found to show significant biological …

Alzheimer's disease (AD) is the most common degenerative disease of the central nervous
system. It is associated with abnormal accumulation of amyloid-β (Aβ) plaques, impaired …

A series of genistein derivatives with carbon spacer-linked alkylbenzylamines were
designed, synthesized and tested as multifunctional agents for the treatment of Alzheimer's …

Alzheimer's disease (AD) is a complex and widespread condition, still not fully understood
and with no cure yet. Amyloid beta (Aβ) peptide is suspected to be a major cause of AD, and …

A novel series of 7-methoxytacrine (7-MEOTA)–donepezil like compounds was synthesized
and tested for their ability to inhibit electric eel acetylcholinesterase (EeAChE), human …

Highlights: ASS2324 is a hybrid compound resulting from the juxtaposition of donepezil and
the propargylamine PF9601N ASS2324 is a multi-target directed propargylamine able to …